Also PFS (HR 1.50; 95 % CI 0.90–2.49) and OS (multivariate HR 1.51; 95 % CI 0.89–2.57) after start of first-line endocrine therapy were both not significantly different between CHEK2 and non-CHEK2 BC patients. This evidence concerns the gene CHEK2 and breast cancer.